As of Tuesday, Axsome Therapeutics Inc.’s (NASDAQ:AXSM) stock closed at $59.93, down from $62.98 the previous day. While Axsome Therapeutics Inc. has underperformed by -4.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AXSM rose by 36.48%, with highs and lows ranging from $82.00 to $20.63, whereas the simple moving average jumped by 5.23% in the last 200 days.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
On January 05, 2023, Piper Sandler started tracking Axsome Therapeutics Inc. (NASDAQ: AXSM) recommending Neutral. A report published by Loop Capital on November 01, 2022, Initiated its previous ‘Buy’ rating for AXSM. Mizuho also rated AXSM shares as ‘Buy’, setting a target price of $76 on the company’s shares in an initiating report dated September 07, 2022. Morgan Stanley August 10, 2021d the rating to Equal-Weight on August 10, 2021, and set its price target from $105 to $34. Berenberg initiated its ‘Buy’ rating for AXSM, as published in its report on June 10, 2021. Jefferies’s report from January 08, 2021 suggests a price prediction of $129 for AXSM shares, giving the stock a ‘Buy’ rating. Mizuho also rated the stock as ‘Buy’.
Analysis of Axsome Therapeutics Inc. (AXSM)
One of the most important indicators of Axsome Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -252.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.50, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and AXSM is recording 950.16K average volume. On a monthly basis, the volatility of the stock is set at 5.40%, whereas on a weekly basis, it is put at 4.51%, with a loss of -2.57% over the past seven days. Furthermore, long-term investors anticipate a median target price of $107.00, showing growth from the present price of $59.93, which can serve as yet another indication of whether AXSM is worth investing in or should be passed over.
How Do You Analyze Axsome Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 18.47%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 60.40% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in AXSM shares?
The recent increase in stakes in AXSM appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in AXSM has increased by 9.84% in the first quarter. The company now owns 3,331,565 shares of the stock, with a value of $227.18 million, following the purchase of 298,541 additional shares during the last quarter. RTW Investments LP made another increased to its shares in AXSM during the first quarter, upping its stake by 58.35%. During the last quarter, the company picked up 1,098,318 additional shares for a total stake of worth $203.24 million, bringing number of shares owned by the company to 2,980,482.
During the first quarter, BlackRock Fund Advisors added a 242,560 position in AXSM. Fairmount Funds Management LLC purchased an additional 0.12 million shares in the last quarter, increasing its holdings by 6.06%, now holding 2.01 million shares worth $137.17 million. AXSM shares are owned by institutional investors to the tune of 60.40% at present.
Leave a Reply